Table 1.
Baseline characteristics of the COVID-19 ICU-cohort
| RRT-cohort | Non-RRT-cohort | |
|---|---|---|
| n = 23 | n = 48 | |
| Age | ||
| Median (range), y | 62 (38–79) | 70 (44–92) |
| ≥ 65 y | 9 (39) | 30 (63) |
| Female | 4 (17) | 13 (27) |
| Admission diagnosis COVID-19 | 18 (78) | 37 (77) |
| Non-renal comorbiditiesa | ||
| Any | 20 (95) | 38 (79) |
| Asthma/COPD | 2 (10) | 3 (6) |
| Atrial Fibrillation | 3 (14) | 12 (25) |
| Coronary Artery Disease | 3 (14) | 10 (21) |
| Hypertension | 12 (57) | 19 (40) |
| Malignancy | 4 (19) | 7 (15) |
| Diabetes mellitus | 4 (19) | 10 (21) |
| Obesity | 3 (14) | 3 (6) |
| Renal | ||
| CKD ≥ G2b | 2 (12) | 7 (15) |
| Acute Kidney injury ≥ Stage 1 | 23 (100) | 30 (63) |
| Creatinine, baselineb, mg/dL | 1.00 (0.80–1.14) | 0.90 (0.70–1.10) |
| Creatinine max, mg/dL | 5.99 (3.32–7.93) | 1.52 (1.04–2.98) |
| SARS-CoV-2-PCR to RRT-initiation, d | 9 (0–39) | |
| Mechanical cardiorespiratory support | ||
| Invasive mechanical ventilation | 22 (96) | 30 (63) |
| Vasopressor administration | 23 (100) | 34 (71) |
| Extracorporeal membrane oxygenation | 10 (43) | 11 (23) |
| Inflammation markers, max. | ||
| C-reactive protein, mg/L (NR: < 5)c | 311 (223–394) | 240 (170–331) |
| Procalcitonin, μg/L (NR: < 0.05) | 18.80 (8.70–43.80) | 0.99 (0.38–3.49) |
| Interleukin 6, ng/L (NR: < 7)d | 1889 (710–14,403) | 320 (112–848) |
| Ferritin, μg/L (NR: 30–400)e | 2565 (1493–3880) | 1612 (807–2719) |
| COVID-19 targeted therapy | ||
| any | 20 (87) | 40 (83) |
| Hydroxychloroquine | 19 (83) | 36 (75) |
| Lopinavir, Ritonavir | 13 (57) | 22 (46) |
| Remdesivir | 0 (0) | 1 (2) |
| Tocilizumab (Anti-IL6) | 3 (13) | 3 (6) |
| Cytokine filter (Cytosorb®) | 1 (4) | 1 (2) |
| Death | 12 (52) | 22 (46) |
Data reported as counts (percentages) or median (interquartile range) unless otherwise indicated. NR: normal range. If not otherwise specified, data represent total cohorts (n = 23 / n = 48). Creatinine max. in RRT-cohort indicates highest value prior to initiation of hemodialysis. aData available from n = 21 / n = 48 individuals in RRT- / Non-RRT-cohort; bn = 17 / n = 48, SI conversion factor to μmol/L, multiply by 88.4; cn = 22 / n = 47; dn = 22 / n = 46; en = 19 / n = 42